CN102576015B - 预测银屑病关节炎患者对抗TNFα抗体的临床反应的血清标记物 - Google Patents

预测银屑病关节炎患者对抗TNFα抗体的临床反应的血清标记物 Download PDF

Info

Publication number
CN102576015B
CN102576015B CN201080044717.6A CN201080044717A CN102576015B CN 102576015 B CN102576015 B CN 102576015B CN 201080044717 A CN201080044717 A CN 201080044717A CN 102576015 B CN102576015 B CN 102576015B
Authority
CN
China
Prior art keywords
patient
serum
value
patients
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080044717.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102576015A (zh
Inventor
C·沃纳
S·维斯瓦纳桑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of CN102576015A publication Critical patent/CN102576015A/zh
Application granted granted Critical
Publication of CN102576015B publication Critical patent/CN102576015B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/52—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving transaminase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201080044717.6A 2009-07-28 2010-07-12 预测银屑病关节炎患者对抗TNFα抗体的临床反应的血清标记物 Expired - Fee Related CN102576015B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22899409P 2009-07-28 2009-07-28
US61/228994 2009-07-28
PCT/US2010/041714 WO2011014349A1 (en) 2009-07-28 2010-07-12 Serum markers predicting clinical response to anti-tnfalpha antibodies in patients with psoriatic arthritis

Publications (2)

Publication Number Publication Date
CN102576015A CN102576015A (zh) 2012-07-11
CN102576015B true CN102576015B (zh) 2014-09-10

Family

ID=43529642

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080044717.6A Expired - Fee Related CN102576015B (zh) 2009-07-28 2010-07-12 预测银屑病关节炎患者对抗TNFα抗体的临床反应的血清标记物

Country Status (7)

Country Link
US (1) US20120178100A1 (enExample)
EP (1) EP2460007A4 (enExample)
CN (1) CN102576015B (enExample)
AU (1) AU2010276665A1 (enExample)
CA (1) CA2769462A1 (enExample)
IN (1) IN2012DN00767A (enExample)
WO (1) WO2011014349A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012228365A1 (en) 2011-03-11 2013-09-19 Katholieke Universiteit Leuven, K.U.Leuven R&D Molecules and methods for inhibition and detection of proteins
RU2014125071A (ru) * 2011-11-21 2015-12-27 Новартис Аг Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa
FR3010188B1 (fr) * 2013-09-05 2017-11-24 Univ Joseph Fourier - Grenoble 1 Procede theragnostique pour le traitement des rhumatismes inflammatoires chroniques
ES3041639T3 (en) * 2015-09-29 2025-11-13 Univ California Biomarkers and methods for assessing psoriatic arthritis disease activity
JP6751157B2 (ja) * 2016-05-12 2020-09-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 疾患を治療するために標的へ向けられた薬物の効力を予測するためのシステム
CN109580759A (zh) * 2017-09-28 2019-04-05 成都飞机工业（集团）有限责任公司 一种四极质谱计
US11232344B2 (en) 2017-10-31 2022-01-25 General Electric Company Multi-task feature selection neural networks
US12089930B2 (en) 2018-03-05 2024-09-17 Marquette University Method and apparatus for non-invasive hemoglobin level prediction
US20220064278A1 (en) * 2019-01-23 2022-03-03 Janssen Biotech, Inc. Anti-TNF Antibody Compositions for Use in Methods for the Treatment of Psoriatic Arthritis
CN114518416B (zh) * 2020-11-20 2024-05-24 上海交通大学医学院附属瑞金医院 一种判断银屑病对il-17a抗体应答反应及其复发的标志物
US20250285762A1 (en) * 2020-12-18 2025-09-11 Nightingale Health Oyj Method for determining whether a subject is at risk of developing a musculoskeletal and/or connective tissue disease
CA3208411A1 (en) * 2021-02-25 2022-09-01 George C. Lee Patient response-based biomarker topology quantification and assessment for multiple tissue types

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103025758A (zh) * 2010-05-14 2013-04-03 Abbvie公司 Il-1结合蛋白

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002048310A2 (en) * 2000-12-15 2002-06-20 Genetics Institute, Llc Methods and compositions for diagnosing and treating rheumatoid arthritis
WO2007123976A2 (en) * 2006-04-18 2007-11-01 The Board Of Trustees Of The Leland Stanford Junior University Antibody profiling for determination of patient responsiveness

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103025758A (zh) * 2010-05-14 2013-04-03 Abbvie公司 Il-1结合蛋白

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Adalimumab for long‐term treatment of psoriatic arthritis: Forty‐eight week data from the adalimumab effectiveness in psoriatic arthritis trial;Dafna D. Gladman;《Arthritis & Rheumatism》;20070130;第56卷(第2期);476-488 *
Golimumab, a new human tumor necrosis factor antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four–week efficacy and safety results of a randomized, placebo-controlled study;Arthur Kavanaugh;《Arthritis & Rheumatism》;20090330;第60卷(第4期);976-986 *

Also Published As

Publication number Publication date
CA2769462A1 (en) 2011-02-03
IN2012DN00767A (enExample) 2015-06-26
CN102576015A (zh) 2012-07-11
WO2011014349A1 (en) 2011-02-03
US20120178100A1 (en) 2012-07-12
AU2010276665A1 (en) 2012-02-23
EP2460007A4 (en) 2013-06-19
EP2460007A1 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
CN102576015B (zh) 预测银屑病关节炎患者对抗TNFα抗体的临床反应的血清标记物
JP5684724B2 (ja) 強直性脊椎炎を有する患者における抗−ＴＮＦα抗体に対する臨床応答を予測する血清マーカー
US20240295553A1 (en) Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity
JP7584486B2 (ja) 乾癬性関節炎の疾患活動性を評価するためのバイオマーカーおよび方法
US12392785B2 (en) Adjusted multi-biomarker disease activity score for inflammatory disease assessment
US20220057395A1 (en) Biomarkers and methods for assessing response to inflammatory disease therapy
CA2950771A1 (en) Biomarkers and methods for measuring and monitoring axial spondyloarthritis disease activity
US20220283157A1 (en) Multiplexed assay kits for evaluation of systemic lupus erythematosus
US20180356419A1 (en) Biomarkers for detection of tuberculosis risk
US20250347703A1 (en) Adjusted multi-biomarker disease activity score for inflammatory disease assessment

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140910

Termination date: 20150712

EXPY Termination of patent right or utility model